Transactive response
DNA-binding protein of 43 kDa (TDP-43) abnormally forms aggregates in certain subtypes of
frontotemporal lobar degeneration (
FTLD) and in
amyotrophic lateral sclerosis (ALS). The pathological forms of TDP-43 have reported to be associated with
poly(ADP-ribose) (PAR), which regulates the properties of these aggregates. A recent study has indicated that
tankyrase, a member of the PAR
polymerase (PARP) family, regulates pathological TDP-43 formation under conditions of stress, and
tankyrase inhibitors suppress TDP-43 aggregate formation and cytotoxicity. Since we reported the development of
tankyrase inhibitors that are more specific than conventional inhibitors, in this study, we examined their effects on the formation of TDP-43 aggregates in cultured cells. Time-lapse imaging showed that TDP-43 aggregates appeared in the nucleus within 30 min of treatment with
sodium arsenite. Several
tankyrase inhibitors suppressed the formation of aggregates and decreased the levels of the
tankyrase protein. Immunohistochemical studies demonstrated that
tankyrase was localized to neuronal cytoplasmic inclusions in the spinal cords of patients with ALS. Moreover, the
tankyrase protein levels were significantly higher in the brains of patients with
FTLD than in the brains of control subjects. These findings suggest that the inhibition of
tankyrase activity protects against TDP-43 toxicity.
Tankyrase inhibitors may be a potential treatment to suppress the progression of
TDP-43 proteinopathies.